A novel STAT3 inhibitor negatively modulates platelet activation and aggregation

Area of Science:

• Hematology
• Molecular Biology
• Pharmacology

Background:

• Signal transducer and activator of transcription 3 (STAT3) is crucial for platelet function.
• Understanding STAT3's role is key to developing anti-thrombotic therapies.

Purpose of the Study:

• To investigate the effects of the STAT3 inhibitor SC99 on platelet activation and aggregation.
• To determine SC99's impact on the STAT3 signaling pathway in platelets.

Main Methods:

• Immunoblotting to assess STAT3 pathway inhibition.
• Platelet aggregation assays using a ChronoLog aggregometer.
• Flow cytometry for P-selectin expression and Annexin-V staining for apoptosis.
• Fluorescence microscopy for platelet spreading analysis.

Main Results:

• SC99 inhibited JAK2 and STAT3 phosphorylation in human platelets.
• SC99 dose-dependently inhibited collagen- and thrombin-induced platelet aggregation.
• SC99 reduced P-selectin expression, fibrinogen binding, platelet spreading, and clot retraction.
• SC99 inhibited platelet aggregation in mice without significantly prolonging bleeding time.

Conclusions:

• SC99 acts as a STAT3 inhibitor, effectively suppressing platelet activation and aggregation.
• SC99 demonstrates potential as a therapeutic agent for thrombotic disorders.